BBP-398 + osimertinib

BBP-398 + osimertinib is an investigational combination therapy for cancer, specifically being developed and clinically evaluated for the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. **BBP-398** is a small-molecule, orally bioavailable, allosteric inhibitor of SHP2 (protein tyrosine phosphatase non-receptor type 11), developed to disrupt aberrant oncogenic signaling downstream of receptor tyrosine kinases by inhibiting the SHP2-mediated RAS/MAPK pathway[1][3][4]. **Osimertinib** is an approved third-generation EGFR tyrosine kinase inhibitor, which irreversibly inhibits both EGFR sensitizing and EGFR T790M resistance mutations. The combination is designed to address resistance to EGFR inhibition in NSCLC—preclinical and early clinical evidence suggests SHP2 inhibition may help restore or enhance sensitivity to EGFR inhibitors in patients with acquired resistance[4]. BBP-398 is being developed jointly by BridgeBio, LianBio, Navire, and Bristol Myers Squibb, with early trials conducted in partnership with AstraZeneca (supplier of osimertinib)[3][4].